# Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma

> **NCT07057596** · PHASE2 · RECRUITING · sponsor: **Grupo Español Multidisciplinar de Melanoma** · enrollment: 19 (estimated)

## Conditions studied

- Mestastatic Uveal Melanoma

## Interventions

- **DRUG:** Tebentafusp

## Key facts

- **NCT ID:** NCT07057596
- **Lead sponsor:** Grupo Español Multidisciplinar de Melanoma
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-18
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07057596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07057596, "Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07057596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*